Scarica l'app Stockscreener
12.32
2.49%
-0.315
Pre-mercato:
12.23
-0.095
-0.77%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$12.64
Aprire:
$12.55
Volume 24 ore:
52,900
Relative Volume:
0.78
Capitalizzazione di mercato:
$23.22M
Reddito:
-
Utile/perdita netta:
$-26.56M
Rapporto P/E:
-0.2787
EPS:
-44.2199
Flusso di cassa netto:
$-28.59M
1 W Prestazione:
+19.78%
1M Prestazione:
+22.27%
6M Prestazione:
+274.62%
1 anno Prestazione:
-20.99%
Intervallo 1D:
$11.68
$12.58
Intervallo di 1 settimana:
$9.25
$13.00
Portata 52W:
$0.61
$19.05
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Nome
Briacell Therapeutics Corp
Settore
Industria
Telefono
(604) 921-1810
Indirizzo
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Confronta BCTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
12.32 | 23.81M | 0 | -26.56M | -28.59M | -44.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-02-14 | Iniziato | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Borsa (BCTX) Ultime notizie
BriaCell Therapeutics : Investor Presentation (1Dec2025 Investor Presentation) - marketscreener.com
BriaCell Therapeutics (BCTXZ) Stock Analysis Report | Financials & Insights - Benzinga
Will BriaCell Therapeutics Corp. Equity Warrant stock outperform Dow Jones indexQuarterly Profit Report & Long-Term Investment Growth Plans - Newser
BriaCell to present positive breast cancer therapy data at SABCS By Investing.com - Investing.com Australia
BriaCell Therapeutics (BCTXW) Stock Analysis Report | Financials & Insights - Benzinga
BriaCell Unveils Promising Clinical Data at 2025 SABCS - TipRanks
BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025 - Investing News Network
BriaCell (BCTX) Shares Positive Clinical Results Ahead of 2025 S - GuruFocus
BriaCell (Nasdaq: BCTX) shares survival, biomarker data; Phase 3 interim readout 1H2026 - Stock Titan
Can BriaCell Therapeutics Corp. stock hit analyst price targetsMarket Risk Analysis & Free Real-Time Market Sentiment Alerts - Newser
(BCT) Strategic Investment Report (BCT:CA) - news.stocktradersdaily.com
Bicara Therapeutics (BCTX) Releases Promising Early Data from Ca - GuruFocus
BriaCell files subsidiary financials and analysis with Canadian regulators By Investing.com - Investing.com Nigeria
BriaCell files subsidiary financials and analysis with Canadian regulators - Investing.com
BriaCell Therapeutics Corp Subsidiary Files Financial Statements - TradingView
(BCT) Comprehensive Trading Strategy Report (BCT:CA) - news.stocktradersdaily.com
What analysts say about BriaCell Therapeutics Corp stockEquity Performance Review & Fast Growing Portfolio Trading - earlytimes.in
BCTXZ Insider Trading - Quiver Quantitative
BriaCell Therapeutics Corp. (BCTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
BriaCell Therapeutics to Present Promising Clinical Data at SABCS 2025 - The Globe and Mail
BriaCell to present positive cancer treatment data at breast cancer symposium By Investing.com - Investing.com Australia
BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025 - Investing News Network
BriaCell to present positive cancer treatment data at breast cancer symposium - Investing.com
BriaCell Therapeutics Brief: Says to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS 2025 - marketscreener.com
BriaCell Therapeutics (NASDAQ: BCTX) Highlights Metastatic Breast Cancer Phase 2/3 Data - Stock Titan
How to Take Advantage of moves in (BCT) (BCT:CA) - news.stocktradersdaily.com
BriaCell Expands Phase 3 Study in Metastatic Breast Cancer - MSN
What analysts say about BriaCell Therapeutics Corp Equity Warrant stockDividend Stability Analysis & Exceptional Capital Trading - earlytimes.in
BriaCell to Present Key Clinical Data at SABCS 2025 - MSN
BriaCell and Receptor.AI Partner on AI- driven Small Molecule Cancer Therapeutics - MarketScreener
BriaCell (BCTX) Partners with Receptor.AI for Innovative Cancer Drug Development - GuruFocus
Briacell and Receptor.AI to collaborate on AI driven small molecule cancer therapeutics - MarketScreener
BriaCell and Receptor.AI Collaborate on AI-Driven Cancer Therapeutics - TipRanks
BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics - The Manila Times
How BriaCell Therapeutics Corp. stock valuations compare to rivalsProfit Target & AI Forecasted Stock Moves - newser.com
Why analysts maintain buy rating on BriaCell Therapeutics Corp. (8BT0) stockSwing Trade & Trade Opportunity Analysis - newser.com
How buyback programs support BriaCell Therapeutics Corp. (8BT0) stock - newser.com
Why BriaCell Therapeutics Corp. (8BT0) stock trades below fair valueGold Moves & AI Enhanced Trading Alerts - newser.com
Published on: 2025-11-20 01:08:24 - newser.com
Why BriaCell Therapeutics Corp. (8BT0) stock remains top ratedMarket Sentiment Report & Entry Point Confirmation Alerts - newser.com
Published on: 2025-11-19 11:18:19 - newser.com
Using portfolio simulators with BriaCell Therapeutics Corp. Equity Warrant includedTrend Reversal & Weekly High Conviction Ideas - newser.com
Briacell Therapeutics Corp Azioni (BCTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.10%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):